|
1
|
Ebell MH, Culp MB and Radke TJ: A
systematic review of symptoms for the diagnosis of ovarian cancer.
Am J Prev Med. 50:384–394. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Reid BM, Permuth JB and Sellers TA:
Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pei H, Yang Y, Cui L, Yang J, Li X, Yang Y
and Duan H: Bisdemethoxycurcumin inhibits ovarian cancer via
reducing oxidative stress mediated MMPs expressions. Sci Rep.
6(28773)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rodriguez-Garcia A, Sharma P, Poussin M,
Boesteanu AC, Minutolo NG, Gitto SB, Omran DK, Robinson MK, Adams
GP, Simpkins F, et al: CAR T Cells Targeting MISIIR for the
Treatment of Ovarian Cancer and Other Gynecologic Malignancies. Mol
Ther. 28:548–560. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Xiao G, Zhang B, Meng J, Wang J, Xu C,
Tang SC, Li X, Zhang J, Liang R, Ren H, et al: miR-367 stimulates
Wnt cascade activation through degrading FBXW7 in NSCLC stem cells.
Cell Cycle. 16:2374–2385. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yeh CH, Bellon M and Nicot C: FBXW7: A
critical tumor suppressor of human cancers. Mol Cancer.
17(115)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhan P, Wang Y, Zhao S, Liu C, Wang Y, Wen
M, Mao JH, Wei G and Zhang P: FBXW7 negatively regulates ENO1
expression and function in colorectal cancer. Lab Invest.
95:995–1004. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhang MX, Wang H and Sun GP:
Tumor-suppressor Fbxw7 targets SIK2 for degradation to interfere
with TORC2-AKT signaling in pancreatic cancer. Cell Biol Int.
44:1900–1910. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Li C, Lin XF, Wang JN and Ren XS: FBXW7
inhibited cell proliferation and invasion regulated by miR-27a
through PI3K/AKT signaling pathway and epithelial-to-mesenchymal
transition in oral squamous cell carcinoma. Eur Rev Med Pharmacol
Sci. 24:3701–3709. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mao JH, Perez-Losada J, Wu D, Delrosario
R, Tsunematsu R, Nakayama KI, Brown K, Bryson S and Balmain A:
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor
gene. Nature. 432:775–779. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhao J, Wang Y, Mu C, Xu Y and Sang J:
MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated
turnover of NICD1 in breast and ovarian cancer cells. Oncogene.
36:5023–5034. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
De La Chesnaye E, Méndez JP, López-Romero
R, De Los Angeles Romero-Tlalolini M, Vergara MD, Salcedo M and
Ojeda SR: FBXW12, a novel F box protein-encoding gene, is deleted
or methylated in some cases of epithelial ovarian cancer. Int J
Clin Exp Pathol. 8:10192–10203. 2015.PubMed/NCBI
|
|
14
|
Kitade S, Onoyama I, Kobayashi H, Yagi H,
Yoshida S, Kato M, Tsunematsu R, Asanoma K, Sonoda K, Wake N, et
al: FBXW7 is involved in the acquisition of the malignant phenotype
in epithelial ovarian tumors. Cancer Sci. 107:1399–1405.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Izumi N, Helker C, Ehling M, Behrens A,
Herzog W and Adams RH: Fbxw7 controls angiogenesis by regulating
endothelial Notch activity. PLoS One. 7(e41116)2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rivera LB and Bergers G: CANCER. Tumor
angiogenesis, from foe to friend. Science. 349:694–695.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ye W, Ni Z, Yicheng S, Pan H, Huang Y,
Xiong Y and Liu T: Anisomycin inhibits angiogenesis in ovarian
cancer by attenuating the molecular sponge effect of the lncRNA
Meg3/miR 421/PDGFRA axis. Int J Oncol. 55:1296–1312.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Carmeliet P: VEGF as a key mediator of
angiogenesis in cancer. Oncology. 69 (Suppl 3):4–10.
2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sadremomtaz A, Mansouri K, Alemzadeh G,
Safa M, Rastaghi AE and Asghari SM: Dual blockade of VEGFR1 and
VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor
growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
Biochim Biophys Acta Gen Subj. 1862:2688–2700. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ai B, Bie Z, Zhang S and Li A: Paclitaxel
targets VEGF-mediated angiogenesis in ovarian cancer treatment. Am
J Cancer Res. 6:1624–1635. 2016.PubMed/NCBI
|
|
22
|
Xu J, Zhang P, Sun H and Liu Y:
LINC01094/miR-577 axis regulates the progression of ovarian cancer.
J Ovarian Res. 13(122)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kappes L, Amer RL, Sommerlatte S, Bashir
G, Plattfaut C, Gieseler F, Gemoll T, Busch H, Altahrawi A,
Al-Sbiei A, et al: Ambrisentan, an endothelin receptor type
A-selective antagonist, inhibits cancer cell migration, invasion,
and metastasis. Sci Rep. 10(15931)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ombrato L and Malanchi I: The EMT
universe: Space between cancer cell dissemination and metastasis
initiation. Crit Rev Oncog. 19:349–361. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ji L, Li X, Zhou Z, Zheng Z, Jin L and
Jiang F: LINC01413/hnRNP-K/ZEB1 axis accelerates cell proliferation
and EMT in colorectal cancer via inducing YAP1/TAZ1 translocation.
Mol Ther Nucleic Acids. 19:546–561. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Peng Y, Li Y, Li Y, Wu A, Fan L, Huang W,
Fu C, Deng Z, Wang K, Zhang Y, et al: HOXC10 promotes tumour
metastasis by regulating the EMT-related gene Slug in ovarian
cancer. Aging (Albany NY). 12:19375–19398. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454.
2002.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Xin L, Zhao R, Lei J, Song J, Yu L, Gao R,
Ha C, Ren Y, Liu X, Liu Y, et al: SND1 acts upstream of SLUG to
regulate the epithelial-mesenchymal transition (EMT) in SKOV3
cells. FASEB J. 33:3795–3806. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Folkman J: Angiogenesis. Annu Rev Med.
57:1–18. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zheng Y, Chen H, Zhao Y, Zhang X, Liu J,
Pan Y, Bai J and Zhang H: Knockdown of FBXO22 inhibits melanoma
cell migration, invasion and angiogenesis via the HIF-1α/VEGF
pathway. Invest New Drugs. 38:20–28. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen L, Lin G, Chen K, Liang R, Wan F,
Zhang C, Tian G and Zhu X: VEGF promotes migration and invasion by
regulating EMT and MMPs in nasopharyngeal carcinoma. J Cancer.
11:7291–7301. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wu XP, Chen H, Wu MT, Peng SG and Zhang L:
Downregulation of miR-182-5p inhibits the proliferation and
invasion of triple-negative breast cancer cells through regulating
TLR4/NF-kappa B pathway activity by targeting FBXW7. Ann Transl
Med. 8(13)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chiang CH, Chu PY, Hou MF and Hung WC:
MiR-182 promotes proliferation and invasion and elevates the HIF-1
alpha-VEGF-A axis in breast cancer cells by targeting FBXW7. Am J
Cancer Res. 6:1785–1798. 2016.PubMed/NCBI
|
|
35
|
Xiao G, Li Y, Wang M, Li X, Qin S, Sun X,
Liang R, Zhang B, Du N, Xu C, et al: FBXW7 suppresses
epithelial-mesenchymal transition and chemo-resistance of
non-small-cell lung cancer cells by targeting snai1 for
ubiquitin-dependent degradation. Cell Prolif.
51(e12473)2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Guo Y, Zhang Z, Wang Z, Liu G, Liu Y and
Wang H: Astragalus polysaccharides inhibit ovarian cancer cell
growth via microRNA-27a/FBXW7 signaling pathway. Biosci Rep: Mar
17, 2020 (Epub ahead of print). doi: 10.1042/BSR20193396.
|
|
37
|
Inan S, Vatansever S, Celik-Ozenci C,
Sanci M, Dicle N and Demir R: Immunolocalizations of VEGF, its
receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors.
Histol Histopathol. 21:1055–1064. 2006.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chiang CH, Chu PY, Hou MF and Hung WC:
MiR-182 promotes proliferation and invasion and elevates the
HIF-1α-VEGF-A axis in breast cancer cells by targeting FBXW7. Am J
Cancer Res. 6:1785–1798. 2016.PubMed/NCBI
|
|
39
|
Liao YJ, Yin XL, Deng Y and Peng XW: PRC1
gene silencing inhibits proliferation, invasion, and angiogenesis
of retinoblastoma cells through the inhibition of the Wnt/β-catenin
signaling pathway. J Cell Biochem. 120:16840–16852. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang F, Zhu W, Yang R, Xie W and Wang D:
LncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer
via activating the Wnt/β-catenin pathway. Mol Cell Biochem.
456:73–83. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Dai J, Wei R, Zhang P and Kong B:
Overexpression of microRNA-195-5p reduces cisplatin resistance and
angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent
GSK3β/β-catenin signaling pathway. J Transl Med.
17(190)2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Shi L, Yang F, Luo F, Liu Y, Zhang F, Zou
M and Liu Q: Evodiamine exerts anti-tumor effects against
hepatocellular carcinoma through inhibiting β-catenin-mediated
angiogenesis. Tumour Biol. 37:12791–12803. 2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Jiang JX, Sun CY, Tian S, Yu C, Chen MY
and Zhang H: Tumor suppressor Fbxw7 antagonizes WNT signaling by
targeting β-catenin for degradation in pancreatic cancer. Tumour
Biol. 37:13893–13902. 2016.PubMed/NCBI View Article : Google Scholar
|
